Controlling Dengue- A review of battery of targets
DOI:
https://doi.org/10.7439/ijap.v6i4.4159Keywords:
Hepatotoxicity, non-invasive methods, invasive method, hepatoprotective drugs, bile duct ligationAbstract
Dengue fever occurs by Infection of mosquito-borne dengue virus and sometimes fatal dengue hemorrhagic fever. Every year cases of dengue infections are increasing.This suggests that the virus is becoming more virulent and its transmission is expanding. Nevertheless, no effective treatment for dengue infection currently exists. This paper has focused several potential targets for antiviral drug development against flavivirus. We discuss the flavivirus genome, NS1, NS2, NS3, Envelope protein and NS5 MTase domain and NS5 RdRp domain as a potential drug targets.Downloads
References
. Chambers, T. J., C. S. Hahn, R. Galler, and C. M. Rice. Flavivirus genome organization, expression, and replication. Annu. Rev. Microbiol 1990; 44:649
. Westaway, E. G. Flavivirus replication strategy. Adv. Virus Res. 1987; 33:45
. Gubler DJ: Dengue and dengue hemorrhagic fever. Clin Microbiol Rev 1998; 11(3): 480-496.
. Ligon BL: Dengue fever and dengue hemorrhagic fever: a review of the history, transmission, treatment, and prevention. Semin Pediatr Infect Dis 2005; 16(1): 60-65.
. OMS. Dengue and Dengue Haemorragic Fever. 2009. Available online: http://www.who.int/mediacentre/factsheets/fs117/en/ (assessed on: 10 June 2012).
. Gubler, D.J.; Meltzer, M. Impact of dengue/dengue hemorrhagic fever on the developing world. Adv. Virus Res. 1999; 53: 35
. Halstead B. Pathogenisis of dengue: challenges to molecular biology, Science 1988; 239 (4839): 476
. Gubler D. J.,
. Libraty D. H., Endy T. P., Houng H. S. H. et al.,
. Vaughn D.W., Green S., Kalayanarooj S. et al.,
. Srikiatkhachorn A.,
. Srikiatkhachorn A., Krautrachue A., Ratanaprakarn W. et al., Natural history of plasma leakage in dengue hemorrhagic fever: a serial ultrasonographic study, Pediatric Infectious Disease Journal, 2007; 26 (4): 283
. Mukhopadhyay S, Kuhn RJ, Rossmann MG. A structural perspective of the flavivirus life cycle. Nat Rev Microbiol 2005; 3:13
. Barba-Spaeth G, Longman RS, Albert ML, Rice CM. Live attenuated yellow fever 17D infects human DCs and allows for presentation of endogenous and recombinant T cell epitopes. J. Exp. Med 2005; 202:1179
. Guzman A, Isturiz RE. Update on the global spread of dengue. Int J Antimicrob Agents 2010; 36S: S40
. Padmanaban Senthilvel1et al. Flavonoid fromCarica papayainhibits NS2B-NS3protease and prevents Dengue 2 viral assembly. Bioinformation 2013; 9(18): 889-895.
. Rothan, H.A. et al. Screening of antiviral activities in medicinal plantsextracts against dengue virus using dengue NS2B-NS3protease assay. Tropical Biomedicine 2014; 31(2): 286
. Rothan et al. Inhibition of dengue NS2B-NS3 protease and viralreplication in Vero cells by recombinantretrocyclin-1. BMC Infectious Diseases, 2012; 12:314.
. Ayub et al. Global Consensus Sequence Development and Analysis of Dengue NS3 Conserved Domains. Bio Research Open Access 2013; 2(5).
. Muslum et al. Allosteric inhibition of the NS2B-NS3 protease from dengue virus. ACS Chem Biol. 2013; 8(12): 2744
. Gebhard LG, Kaufman SB, Gamarnik AV. Novel ATP-Independent RNA Annealing Activity of the Dengue Virus NS3 Helicase. PLoS ONE 2012; 7(4):e36244. doi:10.1371/journal.pone.0036244
. Dong H. et al. Biochemical and genetic characterization of dengue virus methyltransferase. Virology 2010; 405: 568
. Lihui et al. Flavivirus RNA cap methyltransferase: structure, function, and inhibition. Front Biol. 2010; 5(4): 286
. Christian et al. Conformational Flexibility of the Dengue Virus RNA-Dependent RNA polymerase Revealed by a Complex with an Inhibitor. Journal of Virology 2013; 87(9):p. 5291
. Egloff et al. An RNA cap (nucleoside-2-o-)-methyltransferase in the flavivirus RNA polymerase NS5: crystal structure and functional characterization. The EMBO Journal 2002; 21(11):2757-2768.
. Wahala et al. Dengue virus neutralization by human immune sera: Role of envelope protein domain III-reactive antibody Virology 2009; 392:103
. Chiang C-Y, Pan C-H, Hsieh C-H, Tsai J-P, Chen M-Y, et al. Lipidated Dengue-2 Envelope Protein Domain III Independently Stimulates Long-Lasting Neutralizing Antibodies and Reduces the Risk of Antibody-Dependent Enhancement. PLoS Negl Trop Dis 2013; 7(9): e2432.
. Samsa MM, Mondotte JA, Iglesias NG, Assunc
. Chuang et al. Re-evaluation of the pathogenic roles of nonstructural protein 1 and its antibodies during dengue virus infection. Journal of Biomedical Science, 2013; 20:42.
. Qumar et al. Molecular Docking Based Screening of Plant Flavonoids as Dengue NS1 Inhibitors. Bioinformation 2014; 10(7): 460-465.
Downloads
Published
Issue
Section
License
Authors who publish with this journal agree to the following terms:
- Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgment of the work's authorship and initial publication in this journal.
- Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgment of its initial publication in this journal.
- Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access).